Nurah Abdullah Alabidan, Danah Yousif AlAli, Hatim Bakheet Aloufi, Aldhahri Abdulrahman Mansour S., Moayad Khalid Ahmed, Abdulrahman Mohammad A. AL Suqair, Alsalhi M. Turki Abdulaziz, Maani Mahmoud Mohammedsaleh, Maan Bassam Ghulman, Mohammed Saad Alamir Alqahtani, Fatimah Hussain Mohammed Almutawah, Balto, Abdulaziz Abdulrahmana, and Hossam A. El-Kenawy
Journal of Pharmaceutical Research International. :245-254
Since it was declared a worldwide pandemic, COVID-19 has ravaged almost all over the world and has overloaded several health-care systems. The pandemic also resulted in job losses as a result of lengthy shutdowns, which burdened the global economy. Even though significant clinical research progress has led to a better perceiving of the virus (SARS-CoV-2) nature and the disease (COVID-19) management, preventing the virus's spread has become a major concern as SARS-CoV-2 continues to wreak havoc around the world. Several countries suffered from the second or third wave of viral disease outbreaks, primarily caused by the mutation of SARS-CoV-2. Imaging is critical in the diagnosis and follow-up of patients with new coronavirus-infected pneumonia (NCIP). The primary imaging modality in clinically suspected cases is CT scan and it is useful for monitoring imaging changes following therapy. Therefore, CT is regarded as a useful diagnostic technique for clinically suspected cases of COVID-19. CT has the ability to detect patients who have a negative reverse transcription–polymerase chain reaction (RT-PCR) but are highly suspicious of NCIP in terms of clinical problems. In addition, the results of a CT scan may also reveal information concerning the severity of the condition. In this review article, the diagnosis of COVID-19 is discussed and CT characteristics are defined based on the newest research for the diagnosis and management of COVID-19.